Fig. 4From: Efficacy of galactose and adalimumab in patients with resistant focal segmental glomerulosclerosis: report of the font clinical trial groupSerial changes at baseline, week 8, and week 26 in the subjects who were assigned the galactose treatment for (a) Palb; (b) suPAR; and (c) AP5. Each line represents a single subjectBack to article page